MED14

Across TCGA pan-cancer cohorts, MED14 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MED14 data layer compared with 7 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher MED14 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MED14 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SCLC show a favorable association.

KIRC, SCLC, and LGG are the cancer types where MED14 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	II,III,IV	0.778	0.537	.003	60	view →
SCLC	OS	Quartile	All	0.697	0.354	.004	45	view →
LGG	OS	Tertile	All	0.739	0.878	<.001	34	view →
ACC	DFS	Quartile	II,III,IV	0.267	0.777	.004	31	view →
LIHC	DFS	Tertile	All	0.469	0.635	.001	26	view →
LUSC	DFS	Quartile	III,IV	0.319	0.732	<.001	23	view →
PAAD	OS	Median	All	0.337	0.636	.002	23	view →
SARC	OS	Median	All	0.439	0.755	.001	17	view →
UVM	DFS	Tertile	III,IV	0.233	0.772	.007	14	view →
KIRP	OS	Median	II,III,IV	0.459	0.932	.002	14	view →
MESO	OS	Median	All	0.313	0.453	.027	11	view →
THYM	OS	Median	II,III,IV	1.000	0.715	.020	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MED14–KIRC (DFS)

Open the KIRC breakdown →